TB 500 5mg (THYMOSIN BETA 4)

EACH VIAL CONTAINS 5MG OF TB 500

Supplied for Research Purposes Only

This information and product is provided for research purposes only. We do not provide any advice on the usage of these products as UK Law prevents this. Customers should check the legality of this product in their own country prior to purchase.

Benefits and uses:

Improved Recovery

Reduced inflammation

Helps with slow healing injuries to tendons and ligaments, which are examples of connective tissue,

Boosts Muscle injury recovery

Encourages skin damage to heal

Dose:

5mg - 20mg per week (divided over 2 doses)

What is TB-500 Peptide (Thymosin Beta 4)?

The naturally occurring and healing protein known as Thymosin Beta 4 can be found in almost all mammalian and human cells. TB-500 is a synthetic peptide version of Thymosin Beta 4. (TB4). The TB 500 supplement has been shown to have a positive impact on wound healing, injury recovery, flexibility, and inflammation, according to research. These desirable effects are achieved as a result of the influence that TB 500 has on the development of blood cells and blood vessels, as well as cellular differentiation and cell migration. The peptide's ability to regulate actin, a cell-building protein that is essential to the healing and repair of wounds, is a significant contributor to the healing capacity of the substance.

TB-500 Dosage

TB500 is distributed in the form of a freeze-dried powder (also known as lyophilized). When it comes to reconstituting thymosin peptides, research has shown that the best results can be obtained by using bacteriostatic sodium chloride at a concentration of 0.9 percent. Dosages of TB 500 can range anywhere from 5 mg to 20 mg on a weekly basis. In most cases, the treatment consists of two to three injections given once every seven days. After a certain amount of the peptide has been accumulated in the body, the standard practise is to reduce the weekly dosage slightly to a maintenance dosage that is approximately half or less of the initial weekly dose. Once a week is all that is required for the administration of the maintenance dosage.

TB 500 should be kept at room temperature and in an environment with low humidity. It is important that the vial be kept in a dark place. It is possible to keep an opened vial in the refrigerator for up to eight days.

What can TB-500 do?

Research on TB 500 demonstrates multiple properties, which have served as the impetus for a global series of clinical trials of the potential efficacy of thymosin beta-4 in promoting repair of wounds in the skin, cornea, and heart. The thymus gland is responsible for producing thymosin beta 4, which can be found in high concentrations in the fluids surrounding wounds. As a consequence of this, it has been observed to promote the healing of damaged tissue found within the body.

The naturally occurring peptide known as TB-500 can be found in high concentrations in a variety of tissues and fluids, including blood platelets and wound fluid. Peptides TB-500 are not growth factors; rather, they are major actin regulating protein peptides. These are used for research. It has been discovered that TB 500 plays a significant part in the process of protecting, regenerating, and remodelling injured or otherwise damaged tissues. It has also been discovered that the gene for thymosin beta-4 is one of the first genes to be activated in response to an incident of injury.

Thymosin Beta 4 is a naturally occurring peptide that promotes wound healing and can be found in almost all cells of the human and animal body. TB 500 is a synthetically produced version of TB4 that promotes healing and recovery. It does this by assisting in the formation of new blood vessels, muscle tissue fibres, blood cells, and blood cells, as well as by facilitating cell migration. TB 500 provides extremely alluring wound healing effects, making it an appealing option for individuals who are overworked or injured.

What is the function of the TB 500?

Through its effects on actin, TB 500 is able to facilitate the healing process. Through the process of up-regulating this cellular protein, TB 500 is able to take advantage of the beneficial effects that actin has. One of these is the encouragement of the migration and proliferation of cells. As a direct consequence of this, the formation of new blood vessels and the regulation of inflammation contribute to improved rates of healing and recovery. In addition, because of its singular molecular structure, TB 500 is capable of traversing extensive distances within the body. Because of this, it is able to have a "systemic" effect, which allows it to seek out and treat injured parts of the body wherever they may be located. The administration of TB 500 may have additional beneficial effects, including a reduction in inflammation and an increase in flexibility. There have even been reports of the hair regrowing and becoming darker after it has been lost.

What Kind of Negative Effects Does TB 500 Have?

Utilization of Tb500 is associated with a plethora of beneficial effects, some of the most notable of which are enhanced recovery, decreased inflammation, and improved flexibility. The peptide is very helpful in speeding up the recovery process after injuries that take a long time to mend, such as those to connective tissue (including tendons and ligaments). A significant amount of relief is also provided for injuries to the skin and muscles. It appears that TB 500 causes very few, if any, serious adverse side effects, according to the reports that users and researchers from around the world have submitted.

After being injected, the majority of peptides can cause a feeling that is similar to that of dizziness or nausea. Also, flu-like symptoms are prevalent among many other peptides as well. On the other hand, it has been reported that the risk of experiencing any of these undesirable effects as a result of taking TB500 is extremely remote, if it even occurs at all. It would appear that TB 500 is a peptide that is very well tolerated by its users.

The information that is provided on this website is not meant to serve as a substitute for the advice that is provided by your own personal physician, nor is it meant to diagnose, treat, cure, or prevent any disease.

References:

 GRCh38: Ensembl release 89: ENSG00000205542 - Ensembl, May 2017

 "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.

 Gómez-Márquez J, Dosil M, Segade F, Bustelo XR, Pichel JG, Dominguez F, Freire M (Oct 1989). "Thymosin-beta 4 gene. Preliminary characterization and expression in tissues, thymic cells, and lymphocytes". Journal of Immunology. 143 (8): 2740–4. PMID 2677145.

 Lahn BT, Page DC (Oct 1997). "Functional coherence of the human Y chromosome". Science. 278 (5338): 675–80. Bibcode:1997Sci...278..675L. doi:10.1126/science.278.5338.675. PMID 9381176.

 "Entrez Gene: TMSB4X thymosin, beta 4, X-linked".

 "Lists of Recommended and Proposed INNs: List 80". 2018. Archived from the original on September 14, 2008.

 "protein NP_066932". NCBI.

 Hannappel E (September 2007). "beta-Thymosins". Annals of the New York Academy of Sciences. 1112 (1): 21–37. Bibcode:2007NYASA1112...21H. doi:10.1196/annals.1415.018. PMID 17468232. S2CID 222082792.

 Low TL, Hu SK, Goldstein AL (February 1981). "Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations". Proceedings of the National Academy of Sciences of the United States of America. 78 (2): 1162–6. Bibcode:1981PNAS...78.1162L. doi:10.1073/pnas.78.2.1162. PMC 319967. PMID 6940133.

 Banerjee I, Zhang J, Moore-Morris T, Lange S, Shen T, Dalton ND, Gu Y, Peterson KL, Evans SM, Chen J (Feb 2012). "Thymosin beta 4 is dispensable for murine cardiac development and function". Circ Res. 110 (3): 456–64. doi:10.1161/CIRCRESAHA.111.258616. PMC 3739283. PMID 22158707.

 Safer D, Elzinga M, Nachmias VT (March 1991). "Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable". J. Biol. Chem. 266 (7): 4029–32. doi:10.1016/S0021-9258(20)64278-8. PMID 1999398.

 Lodish, Harvey F. (2000). "Chapter 18. Cell Motility and Shape I: Microfilaments. 18.2. The Dynamics of Actin Assembly". Molecular cell biology. San Francisco: W.H. Freeman. ISBN 978-0-7167-3706-3.

 Xue B, Aguda AH, Robinson RC (September 2007). "Models of the actin-bound forms of the beta-thymosins". Annals of the New York Academy of Sciences. 1112 (1): 56–66. Bibcode:2007NYASA1112...56X. doi:10.1196/annals.1415.010. PMID 17468228. S2CID 26966098.

 Jeffery CJ (January 1999). "Moonlighting proteins". Trends Biochem. Sci. 24 (1): 8–11. doi:10.1016/S0968-0004(98)01335-8. PMID 10087914.

 Tompa P, Szász C, Buday L (September 2005). "Structural disorder throws new light on moonlighting". Trends Biochem. Sci. 30 (9): 484–9. doi:10.1016/j.tibs.2005.07.008. PMID 16054818.

 Freeman KW, Bowman BR, Zetter BR (November 2010). "Regenerative protein thymosin {beta}-4 is a novel regulator of purinergic signaling". FASEB J. 25 (3): 907–15. doi:10.1096/fj.10-169417. PMID 21106936. S2CID 1684588.

 Philp D, Kleinman HK (April 2010). "Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide". Annals of the New York Academy of Sciences. 1194 (1): 81–6. Bibcode:2010NYASA1194...81P. doi:10.1111/j.1749-6632.2010.05479.x. PMID 20536453. S2CID 19780581.

 Smart N, Bollini S, Dubé KN, Vieira JM, Zhou B, Davidson S, Yellon D, Riegler J, Price AN, Lythgoe MF, Pu WT, Riley PR (June 2011). "De novo cardiomyocytes from within the activated adult heart after injury". Nature. 474 (7353): 640–4. doi:10.1038/nature10188. PMC 3696525. PMID 21654746.

 Smart N, Riley PR (February 2009). "Derivation of epicardium-derived progenitor cells (EPDCs) from adult epicardium". Current Protocols in Stem Cell Biology. Curr Protoc Stem Cell Biol. Vol. Chapter 2. pp. Unit2C.2. doi:10.1002/9780470151808.sc02c02s8. ISBN 978-0470151808. PMID 19235142.

 Riley PR, Smart N (December 2009). "Thymosin beta4 induces epicardium-derived neovascularization in the adult heart". Biochem. Soc. Trans. 37 (Pt 6): 1218–20. doi:10.1042/BST0371218. PMID 19909250.

 Young JD, Lawrence AJ, MacLean AG, Leung BP, McInnes IB, Canas B, Pappin DJ, Stevenson RD (December 1999). "Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids". Nature Medicine. 5 (12): 1424–7. doi:10.1038/71002. PMID 10581087. S2CID 19680965.

 Crockford D, Turjman N, Allan C, Angel J (April 2010). "Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications". Annals of the New York Academy of Sciences. 1194 (1): 179–89. Bibcode:2010NYASA1194..179C. doi:10.1111/j.1749-6632.2010.05492.x. PMID 20536467. S2CID 29360082.

 Kleinman HK, Sosne G (2016). "Thymosin β4 Promotes Dermal Healing". Thymosins. review. Vitamins and Hormones. Vol. 102. pp. 251–75. doi:10.1016/bs.vh.2016.04.005. ISBN 9780128048184. PMID 27450738.

 Sosne G, Kleinman HK (August 2015). "Primary Mechanisms of Thymosin β4 Repair Activity in Dry Eye Disorders and Other Tissue Injuries". Investigative Ophthalmology & Visual Science. 56 (9): 5110–7. doi:10.1167/iovs.15-16890. PMID 26241398.

 "CAS 2015/A/4059 World Anti-Doping Agency v. Thomas Bellchambers et al., Australian Football League, Australian Sports Anti-Doping Authority" (PDF). 2016. Retrieved 20 March 2016.

 Koh B. "Cronulla Sharks and thymosin beta-4 ... is it doping?". The Conversation.

 Ho EN, Kwok WH, Lau MY, Wong AS, Wan TS, Lam KK, Schiff PJ, Stewart BD (Nov 2012). "Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry". Journal of Chromatography A. 1265: 57–69. doi:10.1016/j.chroma.2012.09.043. PMID 23084823.

 Photo, File (11 January 2016). "Essendon supplements saga: ASADA backs Court of Arbitration for Sport decision to upheld WADA appeal". ABC News (Australian Broadcasting Corporation). {{cite news}}: Missing |author1= (help)

 Ballweber E, Hannappel E, Huff T, Stephan H, Haener M, Taschner N, Stoffler D, Aebi U, Mannherz HG (Jan 2002). "Polymerisation of chemically cross-linked actin:thymosin beta(4) complex to filamentous actin: alteration in helical parameters and visualisation of thymosin beta(4) binding on F-actin". Journal of Molecular Biology. 315 (4): 613–25. doi:10.1006/jmbi.2001.5281. PMID 11812134.

 Safer D, Sosnick TR, Elzinga M (May 1997). "Thymosin beta 4 binds actin in an extended conformation and contacts both the barbed and pointed ends". Biochemistry. 36 (19): 5806–16. doi:10.1021/bi970185v. PMID 9153421.

 Hertzog M, van Heijenoort C, Didry D, Gaudier M, Coutant J, Gigant B, Didelot G, Préat T, Knossow M, Guittet E, Carlier MF (May 2004). "The beta-thymosin/WH2 domain; structural basis for the switch from inhibition to promotion of actin assembly". Cell. 117 (5): 611–23. doi:10.1016/S0092-8674(04)00403-9. PMID 15163409.

 Van Troys M, Dewitte D, Goethals M, Carlier MF, Vandekerckhove J, Ampe C (Jan 1996). "The actin binding site of thymosin beta 4 mapped by mutational analysis". The EMBO Journal. 15 (2): 201–10. doi:10.1002/j.1460-2075.1996.tb00350.x. PMC 449934. PMID 8617195.